Key Takeaways
- J-1 researchers and professors who own US biotech companies or contract research organizations qualify for up to $5M using SSN and EIN — no green card required.
- SBA and SBIR loans have citizenship requirements that exclude most J-1 visa holders — Bankable provides revenue-based funding that bypasses these restrictions entirely.
- Biotech firms with contract revenue, government grants received as income, or client service agreements all qualify if revenue is documented in a US business bank account.
- Decisions arrive within 48 hours — critical for biotech operations that need rapid equipment acquisition, reagent purchasing, or personnel funding to meet contract milestones.
- Bankable's 92% approval rate reflects a revenue-first underwriting approach that evaluates your lab's actual cash flow, not your immigration status or citizenship.
The J-1 Exchange Visitor program was designed, in part, to bring world-class scientific talent to the United States. Professors, researchers, and physicians in J-1 status have built some of the most innovative biotech startups, clinical research organizations, and contract research companies operating in the US today. Their businesses generate real revenue — from government contracts, private research agreements, licensing arrangements, and analytical service clients.
Yet when these J-1 founders seek growth capital, they encounter institutional walls. SBA small business loans require citizenship or permanent residency. SBIR grants flow to the company's principal investigators but the company itself may face ownership restrictions at the SBA level. Bank loans require years of documented tax returns and often condition approval on US citizenship. Bankable was built for exactly this scenario: revenue-generating biotech businesses owned by J-1 visa holders who deserve capital that reflects their company's performance.
What Types of Biotech and Research Organizations Qualify
Bankable funds a broad range of life sciences and research businesses. The common thread is documented US business revenue — monthly deposits into a business bank account that demonstrate your organization's economic activity. Whether your revenue comes from research service contracts, laboratory testing fees, government grants deposited as income, equipment rental, or licensing royalties, Bankable can evaluate it.
- Biotech startups generating service revenue from contract research
- Clinical research organizations (CROs) managing Phase I-IV trial administration
- Contract analytical laboratories providing testing services
- Genomics, proteomics, or diagnostics service companies
- Bioinformatics firms with software service revenue
- Life sciences consulting and advisory businesses
Qualifying Requirements for J-1 Biotech Founders
The qualification process is designed to be fast and document-light. You do not need to submit your scientific IP portfolio, your grant award letters, or your research publications. Bankable evaluates your business on its commercial performance.
| Requirement | Bankable Standard |
|---|---|
| SSN | Required — J-1 researchers and professors qualify |
| EIN | Required — your registered US business entity |
| Business Bank Account | US commercial bank account in the business name |
| Monthly Revenue | $15,000+ in documented business deposits |
| Time in Operation | 3+ months of revenue-generating activity |
| Green Card | Not required |
| IP or Patents as Collateral | Not required |
How Biotech Companies Use Bankable Capital
Biotech and research organizations face both capital intensity and unpredictable revenue timing. Government contract payments can be delayed by weeks. A clinical trial enrollment period may generate heavy upfront costs before any milestone payment arrives. Bankable funding bridges these gaps and funds growth opportunities without requiring you to give up equity.
- Laboratory equipment: Acquire centrifuges, sequencers, mass spectrometers, cell culture equipment, and analytical instruments needed for contract work.
- Reagent and consumable inventory: Maintain adequate supply of research reagents to fulfill contracts without supply chain disruption.
- Personnel hiring: Bring on PhD scientists, lab technicians, regulatory affairs specialists, and business development staff.
- Facility expansion: Lease additional wet lab space, build out cleanroom environments, or expand bio-safety level 2 capacity.
- Regulatory compliance: Fund FDA pre-submission meetings, GLP/GMP compliance audits, and ISO certification processes.
- Working capital bridge: Cover payroll and overhead while awaiting government contract milestone payments or grant disbursements.
Check your Bankability Score today to see what your business qualifies for, or review how SBA 7(a) loans compare to Bankable's revenue-based funding.
Frequently Asked Questions
Yes. Many J-1 researchers and professors form US business entities to commercialize their research. Business ownership does not violate J-1 status, though the activities of the business should be consistent with your program terms. Consult your immigration attorney.
No. Bankable qualifies biotech companies based on monthly revenue, SSN, and EIN. J-1 founders are fully eligible.
Yes. If your company receives SBIR, STTR, or other government grants deposited into your business bank account, these deposits count toward your revenue qualification.
Bankable requires $15,000+ in average monthly deposits. Earlier-stage companies with contract research revenue, service fees, or licensing income that exceeds this threshold qualify.
We underwrite on total deposits to your business bank account regardless of revenue source. Contract research fees, analytical testing service revenue, licensing royalties, and government contract payments all count.
Decisions are issued within 48 hours of receiving your application, SSN, EIN, and 3 months of bank statements. Funding arrives 3–5 business days after approval.
Yes. Bankable's revenue-based funding is non-dilutive and does not conflict with venture capital or angel investment. Many biotech founders use Bankable funding to bridge between funding rounds without diluting equity.
Revenue-based funding repayment is tied to your ongoing revenue. If a major payment is delayed, our team can discuss repayment flexibility. Contact us before a payment is missed.
Yes, provided total monthly deposits meet the $15,000 threshold. We do note client concentration risk in our underwriting — diversified revenue is viewed more favorably, but single-client operations can qualify.
Yes, if the company has its own separate EIN, bank account, and generates revenue independently of the university affiliation.